Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 202 participants.
Also called NCT02657356
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 202 participants
- Sponsor
- Registry
-
NCT02657356
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, Germany, Israel, Japan, Mexico, Netherlands, Philippines, Spain, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT02657356. Randomized; double masking; primary purpose treatment. Start 2016-10-04 (actual); primary completion 2020-05-07 (actual). Results posted on 2023-05-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
- Condition
- Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
- Intervention (Drug)
- Placebo capsules
- Intervention (Drug)
- Bardoxolone methyl capsules
- Lead sponsor
- Biogen
Record details
- Record id
cardio:ct-nct02657356- Content hash
8565148b2f96c693ead906a9353863dc45ea96e5c95a9a84239df0a6f76c1f83